What Roswell Park Does

Roswell Park Comprehensive Cancer Center, founded in 1898, is one of the nation's oldest and most respected cancer research and treatment institutions. Based in Buffalo, New York, it operates as a non-profit, combining a state-of-the-art hospital with a premier research institute. Its mission encompasses patient care, cancer research, and education. The center treats a high volume of patients with complex oncology needs and conducts groundbreaking clinical and translational research, generating immense amounts of clinical trial data, genomic sequences, and medical imaging. This dual role as a care provider and research engine creates a unique data-rich environment.

Why AI Matters at This Scale

For an organization of Roswell Park's size (1,001-5,000 employees) and sector, AI is not a luxury but a strategic imperative to manage complexity and advance its mission. The scale of operations means inefficiencies in scheduling or resource use are magnified, impacting both costs and patient access. More critically, the sheer volume and complexity of multimodal patient data—from electronic health records (EHRs) and medical imaging to genomic sequencing—exceed human cognitive capacity for pattern recognition. AI provides the tools to synthesize this information, unlocking insights for earlier detection, personalized treatment, and accelerated research. At this institutional scale, successful AI deployment can create significant competitive advantages in patient outcomes, research prestige, and operational sustainability.

Concrete AI Opportunities with ROI Framing

1. Precision Oncology Platforms: Integrating AI to analyze genomic, proteomic, and clinical data can identify optimal, personalized treatment plans. The ROI is measured in improved patient survival rates, reduced trial-and-error chemotherapy (lowering costs and side effects), and strengthened positioning as a top-tier research center attracting grants and partnerships.

2. Operational Efficiency for High-Cost Assets: AI-driven predictive scheduling for operating rooms, infusion chairs, and advanced imaging equipment (like PET-CT scanners) can maximize utilization of these high-capital assets. For a large hospital, a few percentage points of improved efficiency can translate to millions in annual revenue generation or cost avoidance, while reducing patient wait times.

3. Clinical Trial Acceleration: Natural Language Processing (NLP) can automate the screening of thousands of patient records to identify eligible candidates for specific clinical trials. This directly addresses a major bottleneck in oncology research. The ROI includes faster trial completion (getting therapies to market sooner), increased trial revenue, and more patients accessing cutting-edge treatments.

Deployment Risks Specific to This Size Band

Organizations in the 1,001-5,000 employee range face distinct AI implementation risks. Integration Complexity: Legacy IT systems, including major EHR platforms and siloed research databases, are difficult and expensive to integrate into a unified AI-ready data lake. Talent Retention: While large enough to hire AI talent, they may struggle to compete with the compensation and agility of tech giants or well-funded startups, leading to talent churn. Change Management: Scaling AI from departmental pilots to enterprise-wide solutions requires coordinating a large, diverse workforce of clinicians, researchers, and administrators, where resistance to altered workflows can stall adoption. Regulatory Scrutiny: As a prominent institution, any clinical AI application will face intense regulatory and ethical scrutiny, requiring robust validation frameworks and potentially slowing time-to-value.